Project Remission launches clinician toolkit

Obesity medicine is having a very specific growing pain. Powerful drugs are getting prescribed fast, but the day-to-day care around them — food, activity, side effects, muscle loss, long-term maintenance, and what happens if someone stops — is often much less standardized. That is the gap the American College of Lifestyle Medicine is trying to fill. On May 5, 2026, ACLM rolled out a new Obesity Medications & Lifestyle Medicine Toolkit for clinicians. The point is not to replace GLP-1s or other anti-obesity drugs. It is to give doctors and care teams a more operational playbook for using those drugs alongside lifestyle treatment, from starting therapy to tapering or discontinuation when that makes sense. (prnewswire.com) ### What actually launched? The new item is a clinician toolkit, not a consumer guide and not a new drug program. ACLM says it is built for real-world obesity practice and is meant to help providers integrate obesity medications with lifestyle medicine instead of treating medication as a stand-alone fix. (([prnewswire.com)### Why does that need a toolkit? Because the hard part is no longer just getting access to these medications. The hard part is managing everything around them. Patients may eat less but also lose lean mass. They may need help with protein intake, resistance training, sleep, stress, and sustainable routines(prnewswire.com)tween prescribing a drug and delivering durable obesity care. (prnewswire.com) ### What is lifestyle medicine doing here? Basically, ACLM is arguing that obesity drugs work better when they sit inside a broader treatment model. That model centers on nutrition, physical activity, sleep, stress management, social connection, and avoidance of risky substances — the same six-pillar framew(prnewswire.com) metabolic improvements going. (lifestylemedicine.org) ### Where does Project Remission fit? This is where the story gets a little confusing, because “Project Remission” is a separate ACLM initiative. It is not the new obesity toolkit. Project Remission is ACLM’s broader type 2 diabetes effort — a digital series and education push built around the idea that intensive lifestyle treatment can sometimes move diabetes from management toward remission. ACLM launched that project in late March 2026 with Content With Purpose. (news-medical.net) ### So why are people connecting the two? Because they are clearly part of the same strategic direction. Obesity, insulin resistance, and type 2 diabetes overlap heavily in clinical practice. A toolkit on combining obesity medications with lifestyle care fits neatly beside a remission-focused diabetes campaign. That does not mean ACLM announced a single merged prog(news-medical.net)more aggressively, and use medication as one piece of a longer-term metabolic care plan. (prnewswire.com) ### Is deprescribing part of this? For the obesity toolkit, ACLM explicitly says the resource covers the full course of medication use, including discontinuation when appropriate. But the more detailed language about deprescribing glucose-lowering drugs belongs more naturally to ACLM’s diabetes-remission work and guideline ecosystem than to the obesity-toolkit announcement itself. So the broad idea is there, but the original framing mixes two related ACLM efforts together. (learning.lifestylemedicine.org) ### What is the real takeaway? The news is less “ACLM invented a new obesity treatment” and more “ACLM is trying to professionalize the messy middle.” Drugs changed obesity care fast. Now the clinical infrastructure is catching up. This toolkit is one sign of that — and Project Remission shows ACLM wants the same playbook to matter in diabetes too. (prnews([learning.lifestylemedicine.org)s-with-obesity-medications-302762639.html))